Gp100 (280-288) A288V HLA-A*0201 antigen peptide – YLEPGPVTV

gp100 (280-288) A288V HLA-A*0201 antigen peptide – YLEPGPVTV SB-PEPTIDE offers gp100 (280-288) A288V variant peptide – YLEPGPVTV for its promising use in immunotherapy. gp100 protein: potent melanoma-specific antigen gp100 (Uniprot: P40967) 661 amino acids long type I transmembrane glycoprotein, also known as premelanosome protein (PMEL) for the gene encoding it, is primarily known for its crucial role in melanosome morphogenesis and pigmentation. Indeed, it orchestrates the maturation of these organelles, that are responsible for melanin synthesis, storage, and transport. More than its implication in melanosome maturation, melanogenesis, biogenesis, and melanin polymerization, gp100 has gained significant attention and recognition as tumor-associated antigen (TAA) . Hance, its dynamic and multifaceted nature piqued the interest of researchers and immunobiologists to explore PMEL’s potential in shaping the future of cancer treatment. gp100 280-288 immunogenic epitope – YLEPGPVTA Fragments of this protein hold the key to unlocking the body’s natural defense mechanisms against melanoma and have thus been harnessed to develop cancer vaccines. Specifically, gp100 (280-288) HLA-A*0201 epitope – YLEPGPVTA (IEDB: 74638) has exhibited its potential as a robust immunogen, thanks to its capacity to induce cytotoxic T lymphocyte (CTL) responses at remarkably low concentrations (<pM) . Additionally, studies have even shown that nonamer peptide is naturally processed and presented in its DNA-encoded form, making it an ideal candidate for tumor vaccine strategies. gp100 (280-288) A288V variant peptide – YLEPGPVTV Strategic mutation of the C-terminal gp100 280-288 peptide’s alanine to valine in the derived gp100 (280-288) A288V variant peptide YLEPGPVTV (IEDB: 74641) demonstrated enhanced binding to human leukocyte antigen (HLA) molecules, while maintaining comparable affinity to that of its wild type version (YLEPGPVTA) for its T-cell receptor (TCR) . With the natural immunogenic characteristics of gp100 (280-288) fragment and its improved TCR binding capability, YLEPGPVTV peptide represents a pioneering step in optimizing immunotherapy.